Research ArticleCORONAVIRUS

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

See allHide authors and affiliations

Science Translational Medicine  12 May 2021:
Vol. 13, Issue 593, eabf1906
DOI: 10.1126/scitranslmed.abf1906

Article Information

vol. 13 no. 593

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication October 9, 2020
  • Resubmitted January 19, 2021
  • Accepted for publication March 31, 2021
  • .

Article Versions

Author Information

  1. Bryan E. Jones1,*,
  2. Patricia L. Brown-Augsburger2,
  3. Kizzmekia S. Corbett3,
  4. Kathryn Westendorf4,
  5. Julian Davies1,
  6. Thomas P. Cujec1,
  7. Christopher M. Wiethoff2,
  8. Jamie L. Blackbourne2,
  9. Beverly A. Heinz2,
  10. Denisa Foster1,
  11. Richard E. Higgs2,
  12. Deepa Balasubramaniam1,
  13. Lingshu Wang3,
  14. Yi Zhang3,
  15. Eun Sung Yang3,
  16. Roza Bidshahri4,
  17. Lucas Kraft4,
  18. Yuri Hwang4,
  19. Stefanie Žentelis4,
  20. Kevin R. Jepson4,
  21. Rodrigo Goya4,
  22. Maia A. Smith4,
  23. David W. Collins4,
  24. Samuel J. Hinshaw4,
  25. Sean A. Tycho4,
  26. Davide Pellacani4,
  27. Ping Xiang4,
  28. Krithika Muthuraman4,
  29. Solmaz Sobhanifar4,
  30. Marissa H. Piper1,
  31. Franz J. Triana1,
  32. Jorg Hendle1,
  33. Anna Pustilnik1,
  34. Andrew C. Adams2,
  35. Shawn J. Berens2,
  36. Ralph S. Baric5,
  37. David R. Martinez5,
  38. Robert W. Cross6,
  39. Thomas W. Geisbert6,
  40. Viktoriya Borisevich6,
  41. Olubukola Abiona3,
  42. Hayley M. Belli7,
  43. Maren de Vries8,
  44. Adil Mohamed8,
  45. Meike Dittmann8,
  46. Marie I. Samanovic9,
  47. Mark J. Mulligan9,
  48. Jory A. Goldsmith10,
  49. Ching-Lin Hsieh10,
  50. Nicole V. Johnson10,
  51. Daniel Wrapp10,
  52. Jason S. McLellan10,
  53. Bryan C. Barnhart4,
  54. Barney S. Graham3,
  55. John R. Mascola3,
  56. Carl L. Hansen4 and
  57. Ester Falconer4,*
  1. 1Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
  2. 2Eli Lilly and Company, Indianapolis, IN 46225, USA.
  3. 3Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  4. 4AbCellera Biologics Inc., Vancouver, BC V5Y0A1, Canada.
  5. 5University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  6. 6Galveston National Laboratory and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
  7. 7Department of Population Health, Division of Biostatistics, New York University Grossman School of Medicine, New York, NY 10016, USA.
  8. 8Department of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA.
  9. 9NYU Langone Vaccine Center, Department of Medicine, Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, NY 10016, USA.
  10. 10Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
  1. *Corresponding author. Email: jones_bryan_edward{at}lilly.com (B.E.J.); ester.falconer{at}abcellera.com (E.F.)

Altmetric

Article usage

Article usage: April 2021 to July 2021

AbstractFullPdf
Apr 2021242104142369
May 2021298113741702
Jun 2021582496577
Jul 20212311684652

Stay Connected to Science Translational Medicine

Navigate This Article